LSP Dementia Fund

LSP Dementia Fund is an investment firm.

Active

Updated: Mar 15, 2026 ·

About

LSP Dementia Fund is a venture capital fund established in 2020, specializing in investments within the life sciences sector. Managed by EQT Life Sciences, the fund is dedicated to supporting innovative companies that are developing treatments and technologies for neurodegenerative diseases, with a particular focus on dementia. It operates from Amsterdam, Netherlands, as part of the broader EQT Group's life sciences initiatives.

The fund's strategic approach involves identifying and backing ventures that aim to address the complex challenges associated with dementia. Its portfolio companies have collectively initiated 15 clinical studies and provided treatment to over 7,000 patients globally, underscoring its commitment to advancing medical solutions in this field.

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Feb 9, 2026	Aerska	$39.0M Series A	age1, LSP Dementia Fund	Iaso Ventures

Financial History

Total Raised

N/A

Valuation

N/A

Deep Dive

LSP Dementia Fund is a venture capital fund founded in 2020, operating under the management of EQT Life Sciences. Headquartered in Amsterdam, Netherlands, the fund is strategically positioned within the European life sciences ecosystem to identify and support emerging companies. Its core mission is to drive innovation in the treatment and technology development for neurodegenerative diseases, with a primary emphasis on dementia.

The fund's investment thesis centers on backing companies that are at the forefront of scientific discovery and therapeutic development for these complex conditions. This includes a range of approaches, from novel drug candidates to advanced diagnostic tools and patient care technologies. The objective is to foster breakthroughs that can significantly improve patient outcomes and quality of life for individuals affected by dementia.

Operationally, LSP Dementia Fund has demonstrated a tangible impact through its portfolio companies. These ventures have collectively initiated 15 clinical studies, reflecting a commitment to rigorous scientific validation and development. Furthermore, the treatments and technologies supported by the fund have reached over 7,000 patients globally, indicating a broad reach and potential for widespread benefit.

The management of the LSP Dementia Fund is overseen by EQT Life Sciences, with Professor Philip Scheltens, a recognized dementia scientist and thought leader, playing a key role in its direction. This leadership brings specialized expertise and a deep understanding of the scientific and clinical landscape of dementia, guiding the fund's investment decisions.

As an integral part of the EQT Group, LSP Dementia Fund leverages a broader network and resources to support its portfolio. Its dedicated focus on dementia positions it as a specialized investor aiming to contribute to solutions for one of the most pressing global health challenges. The fund continues to seek opportunities that align with its mission of combating neurodegenerative diseases through innovative capital deployment.

Sources

Frequently Asked Questions

Who manages the LSP Dementia Fund?

The LSP Dementia Fund is managed by EQT Life Sciences, with Professor Philip Scheltens, a recognized dementia scientist and thought leader, playing a key role in its management.

Frequently Asked Questions

Who manages the LSP Dementia Fund?

The LSP Dementia Fund is managed by EQT Life Sciences, with Professor Philip Scheltens, a recognized dementia scientist and thought leader, playing a key role in its management.